Hydantoin based inhibitors of MMP13-Discovery of AZD6605

被引：20

作者：

De Savi, Chris ^{[1
,2
]}

Waterson, David ^{[2
]}

Pape, Andrew ^{[2
]}

Lamont, Scott ^{[2
]}

Hadley, Elma ^{[2
]}

Mills, Mark ^{[2
]}

Page, Ken M. ^{[2
]}

Bowyer, Jonathan ^{[2
]}

Maciewicz, Rose A. ^{[2
]}

机构：

[1] AstraZeneca R&D Boston, Oncol Innovat Med, Waltham, MA 02451 USA

[2] AstraZeneca R&D, Resp & Inflammat Innovat Med, SE-43813 Molndal, Sweden

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 16期

关键词：

MMP13; Hydantoin; Zinc binder; Cyp P450; Lead optimisation; OSTEOARTHRITIS; CLASSIFICATION; OPTIMIZATION; BINDING; MODEL;

D O I：

10.1016/j.bmcl.2013.05.089

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

Piperidine ether and aryl piperazine hydantoins are reported as potent inhibitors of MMP13. A medicinal chemistry campaign focused on replacing the reverse hydroxamate zinc binding group associated with historical inhibitors with a hydantoin zinc binding group then optimising MMP13 potency, solubility and DMPK properties whilst maintaining good selectivity over MMP14. A number of high quality candidates were progressed and following rat and dog safety evaluation, AZD6605 (3m) was identified as a candidate drug. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：4705 / 4712

页数：8

共 32 条

[1]

DEVELOPMENT OF CRITERIA FOR THE CLASSIFICATION AND REPORTING OF OSTEOARTHRITIS - CLASSIFICATION OF OSTEOARTHRITIS OF THE KNEE [J].

ALTMAN, R ;

ASCH, E ;

BLOCH, D ;

BOLE, G ;

BORENSTEIN, D ;

BRANDT, K ;

CHRISTY, W ;

COOKE, TD ;

GREENWALD, R ;

HOCHBERG, M ;

HOWELL, D ;

KAPLAN, D ;

KOOPMAN, W ;

LONGLEY, S ;

MANKIN, H ;

MCSHANE, DJ ;

MEDSGER, T ;

MEENAN, R ;

MIKKELSEN, W ;

MOSKOWITZ, R ;

MURPHY, W ;

ROTHSCHILD, B ;

SEGAL, M ;

SOKOLOFF, L ;

WOLFE, F .

ARTHRITIS AND RHEUMATISM, 1986, 29 (08) :1039-1049

[2]

[Anonymous], GLOBAL BURDEN OSTEOA

[3]

SPONTANEOUS CARTILAGE DEGENERATION IN GUINEA-PIGS [J].

BENDELE, AM ;

HULMAN, JF .

ARTHRITIS AND RHEUMATISM, 1988, 31 (04) :561-565

[4]

Bigg Heather F., 2001, Current Opinion in Pharmacology, V1, P314, DOI 10.1016/S1471-4892(01)00055-8

[5]

Bridgland-Taylor M. H., 2006, Journal of Pharmacological and Toxicological Methods, V54, P189, DOI 10.1016/j.vascn.2006.02.003

[6]

Ongoing trials with matrix metalloproteinase inhibitors [J].

Brown, PD .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) :2167-2177

[7]

Conaghan P., 2008, Osteoarthritis: National Clinical Guideline for Care and Management in Adults

[8]

De Savi C., 2011, MED CHEM LETT, V22, P271

[9]

Selective non zinc binding inhibitors of MMP13 [J].

De Savi, Chris ;

Morley, Andrew D. ;

Ting, Attilla ;

Nash, Ian ;

Karabelas, Kostas ;

Wood, Christine M. ;

James, Michael ;

Norris, Stephen J. ;

Karoutchi, Galith ;

Rankine, Neil ;

Hamlin, Gordon ;

MacFaul, Philip A. ;

Ryan, David ;

Baker, Sarah V. ;

Hargreaves, David ;

Gerhardt, Stefan .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (14) :4215-4219

[10]

Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis [J].

De Savi, Chris ;

Pape, Andrew ;

Sawyer, Yvonne ;

Milne, David ;

Davies, Chris ;

Cumming, John G. ;

Ting, Attilla ;

Lamont, Scott ;

Smith, Peter D. ;

Tart, Jonathon ;

Page, Ken ;

Moore, Peter .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (11) :3301-3306

← 1 2 3 4 →